Cơ hội và thách thức trong sàng lọc quy mô lớn đối với rung nhĩ

Aliot E, Brandes A, Eckardt L et al (2015) The EAST study: redefining the role of rhythmcontrol therapy in atrial fibrillation: EAST, the early treatment of atrial fibrillation for stroke prevention trial. Eur Heart J 36:255–256 Aronsson M, Svennberg E, Rosenqvist M et al (2015) Cost-effectiveness of mass screening for untreated atrial fibrillation using intermittent ECG recording. Europace 17:1023–1029 Brambatti M, Connolly SJ, Gold MR et al (2014) Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation 129:2094–2099 Chan NY, Choy CC (2017) Screening for atrial fibrillation in 13 122 Hong Kong citizens with smartphone electrocardiogram. Heart 103:24–31 Cosio FG, Aliot E, Botto GL et al (2008) Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode. Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of. Cardiology 10:21–27 Fitzmaurice DA, Hobbs FD, Jowett S et al (2007) Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. BMJ 335:383 Freedman B, Camm J, Calkins H et al (2017) Screening for atrial fibrillation: a report of the AF-SCREEN international collaboration. Circulation 135:1851–1867 Hart RG, Sharma M, Mundl H et al (2016) Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: design of the NAVIGATE ESUS randomized trial. Eur Stroke J 1:146–154 Healey JS, Alings M, Ha A et al (2017) Subclinical atrial fibrillation in older patients. Circulation 136:1276–1283 January CT, Wann LS, Alpert JS et al (2014) 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64:e1–76 Kaasenbrood F, Hollander M, Rutten FH et al (2016) Yield of screening for atrial fibrillation in primary care with a hand-held, single-lead electrocardiogram device during influenza vaccination. Europace 18:1514–1520 Kirchhof P, Benussi S, Kotecha D et al (2016) 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37:2893–2962 Lau DH, Nattel S, Kalman JM et al (2017) Modifiable risk factors and atrial fibrillation. Circulation 136:583–596 Lowres N, Neubeck L, Redfern J et al (2013) Screening to identify unknown atrial fibrillation. A systematic review. Thromb Haemost 110:213–222 Lowres N, Neubeck L, Salkeld G et al (2014) Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. Thromb Haemost 111:1167–1176 Mairesse GH, Moran P, Van Gelder IC et al (2017) Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE). Europace 19:1589–1623 Nieuwlaat R, Capucci A, Camm AJ et al (2005) Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 26:2422–2434 Ogilvie IM, Newton N, Welner SA et al (2010) Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 123:638–645 Reiffel JA, Verma A, Kowey PR et al (2017) Incidence of previously undiagnosed atrial fibrillation using insertable cardiac monitors in a high-risk population: the REVEAL AF study. Jama Cardiol 2(10):1120–1127. https://doi.org/10.1001/jamacardio.2017.3180 Ruff CT, Giugliano RP, Braunwald E et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383:955–962 Sandhu RK, Bakal JA, Ezekowitz JA et al (2011) Risk stratification schemes, anticoagulation use and outcomes: the risk—treatment paradox in patients with newly diagnosed non-valvular atrial fibrillation. Heart 97:2046–2050 Sandhu RK, Dolovich L, Deif B et al (2016) High prevalence of modifiable stroke risk factors identified in a pharmacy-based screening programme. Open Heart 3:e515 Siontis KC, Gersh BJ, Killian JM et al (2016) Typical, atypical, and asymptomatic presentations of new-onset atrial fibrillation in the community: characteristics and prognostic implications. Heart Rhythm 13:1418–1424 Svennberg E, Engdahl J, Al-Khalili F et al (2015) Mass screening for untreated atrial fibrillation: the STROKESTOP study. Circulation 131:2176–2184 Tieleman RG, Plantinga Y, Rinkes D et al (2014) Validation and clinical use of a novel diagnostic device for screening of atrial fibrillation. Europace 16:1291–1295 Vanassche T, Lauw MN, Eikelboom JW et al (2015) Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. Eur Heart J 36:281–287a Wilson JM, Jungner YG (1968) Principles and practice of mass screening for disease. Bol Oficina Sanit Panam 65:281–393 Writing Group, Mozaffarian D, Benjamin EJ et al (2016) Heart Disease and Stroke Statistics-2016 update: a report from the American Heart Association. Circulation 133:e38–e360 Yiin GS, Howard DP, Paul NL et al (2014) Age-specific incidence, outcome, cost, and projected future burden of atrial fibrillation-related embolic vascular events: a population-based study. Circulation 130:1236–1244